Skip to main navigation menu Skip to main content Skip to site footer
DOI:
https://doi.org/10.4414/smw.2019.20133

Author reply to technical comment

Vol. 149 No. 3940 (2019)

Reply to comment by Carratù P, et al. on: Hostettler K, et al. Bosentan for patients with steroid-resistant pulmonary sarcoidosis: a randomised controlled trial

  • Katrin E. Hostettler
  • Martin H. Brutsche
Cite this as:
Swiss Med Wkly. 2019;149:w20133
Published
30.09.2019

References

  1. Carratù P, Dragonieri S, Resta O. Comment on: Hostettler K, et al. Bosentan for patients with steroid-resistant pulmonary sarcoidosis: a randomised controlled trial. Swiss Med Wkly. 2019;149:w20132. doi:https://doi.org/10.4414/smw.2019.20132
  2. Hostettler K, Baty F, Kleiner R, Junker L, Tamm M, Brutsche M. Bosentan for patients with steroid-resistant pulmonary sarcoidosis: a randomised controlled trial. Swiss Med Wkly. 2018;148:w14677. doi:.https://doi.org/10.4414/smw.2018.14677
  3. Sofia M, Mormile M, Faraone S, Alifano M, Carratù P, Carratù L. Endothelin-1 excretion in urine in active pulmonary sarcoidosis and in other interstitial lung diseases. Sarcoidosis. 1995;12(2):118–23.

Most read articles by the same author(s)